Antiangiogenic agents: current limits in thoracic oncology

被引：0
|
作者：
Dansin, Eric [1 ]
Lauridant, Geraldine [1 ]
Chahine, Bachar [1 ]
机构：
[1] CLCC Oscar Lambret, Dept Cancerol Gen, F-59020 Lille, France
来源：
BULLETIN DU CANCER | 2012年 / 99卷 / 11期
关键词：
antiangiogenic agent; multi-targeted tyrosine kinase inhibitor; bevacizumab; lung cancer; thoracic oncology; CELL-LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED PHASE-II; ANGIOGENESIS INHIBITOR BEVACIZUMAB; ARTERIAL THROMBOEMBOLIC EVENTS; PACLITAXEL PLUS BEVACIZUMAB; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; COST-EFFECTIVENESS; 1ST-LINE BEVACIZUMAB;
D O I：
10.1684/bdc.2012.1655
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Antiangiogenic agents appear as major therapeutic options in renal, colorectal and breast cancer. Their part in thoracic oncology is still limited today except for bevacizumab. We review the current limits of antiangiogenic agents in terms of efficacy, activity, tolerance and therapeutic strategies. Problems about predictive biomarkers and cost-effectiveness of antiangiogenic agents in thoracic oncology are also mentioned.
引用
收藏
页码：1083 / 1091
页数：9
相关论文
共 50 条
  • [31] Understanding resistance to antiangiogenic agents
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2014, 13 (10) : 726 - 726
  • [32] Interferons as antiangiogenic agents.
    Lindner D.J.
    Current Oncology Reports, 2002, 4 (6) : 510 - 514
  • [33] Antiangiogenic agents in breast cancer
    Salter, John T.
    Miller, Kathy D.
    CANCER INVESTIGATION, 2007, 25 (07) : 518 - 526
  • [34] Comment on "Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service"
    Rezazadeh, Amir
    Taghizadeh-Ghehi, Maryam
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (02) : 335 - 336
  • [35] LIMITS TO ONCOLOGY
    STOKER, M
    NATURE, 1975, 254 (5501) : 547 - 548
  • [36] Current and future strategies for Antiangiogenic agents in non-small-cell lung cancer
    Herbst, Roy S.
    CLINICAL LUNG CANCER, 2008, 9 : S50 - S50
  • [37] Antiplatelet agents and acute coronary syndromes: Status and current limits
    Ferrari, E.
    ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS, 2012, 4 (03) : 232 - 235
  • [38] Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology
    Gamarra, Fernando
    Noel, Julie-Lyn
    Brunelli, Alessandro
    Dingemans, Anne-Marie C.
    Felip, Enriqueta
    Gaga, Mina
    Grigoriu, Bogdan Dragos
    Hardavella, Georgia
    Huber, Rudolf M.
    Janes, Samuel
    Massard, Gilbert
    Putora, Paul Martin
    Sculier, Jean-Paul
    Schnabel, Philipp A.
    Ramella, Sara
    Van Raemdonck, Dirk
    Meert, Anne-Pascale
    BREATHE, 2016, 12 (03) : 249 - 255
  • [39] Thoracic oncology in Europe: the ERS action plan by the Thoracic Oncology Assembly
    Sculier, J-P.
    Vansteenkiste, J.
    Schoenfeld, N.
    Scherpereel, A.
    EUROPEAN RESPIRATORY JOURNAL, 2010, 36 (06) : 1227 - 1228
  • [40] THE CLINICAL-EXPERIENCE WITH ANTIANGIOGENIC AGENTS
    MARSHALL, JL
    HAWKINS, MJ
    BREAST CANCER RESEARCH AND TREATMENT, 1995, 36 (02) : 253 - 261
12345